- Report
- May 2025
- 187 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- May 2025
- 183 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- July 2025
- 391 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- August 2024
- 54 Pages
Global
From €1713EUR$1,950USD£1,478GBP
Co Development Partnering in the biotechnology industry is a form of collaboration between two or more companies to develop a product or technology. It is a way for companies to share resources, expertise, and risk in order to bring a product to market faster and more cost-effectively. Companies may partner to develop a new drug, device, or diagnostic, or to improve an existing product. The partnering process typically involves a series of negotiations and agreements between the companies, and may include the sharing of intellectual property, technology, and financial resources.
Co Development Partnering is becoming increasingly popular in the biotechnology industry, as it allows companies to leverage each other’s strengths and resources to bring products to market more quickly and cost-effectively.
Some companies in the Co Development Partnering market include AstraZeneca, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more